Thrombotic Reactant Markers in Non-ST Segment Elevation Acute Coronary Syndromes Treated with Either Enoxaparin (Low Molecular Weight Heparin) or Unfractionated Heparin
| 详细信息 | 推荐本文 | |
- 作者：Enrique Gurfinkel ; Ernesto Duronto ; Cecilia Colorio ; Gerardo Bozovich ; Marc Cohen and Branco Mautner
- 关键词：unstable angina ; thrombotic markers ; low molecular weight heparin ; unfractionated heparin
- 刊名：Journal of Thrombosis and Thrombolysis
- 出版时间：1999
- 出版年：1999
- 期刊代码：91_09295305
- 类别：bio
- 卷：8
- 期：3
- 页码：227-232
- 数据来源：sp
摘要
Background: This study was designed to analyze the impact of treatment with either unfractionated heparin or enoxaparin (low molecular weight heparin) on plasma markers of thrombotic and endogenous thrombolytic activity in patients with non-ST segment elevation acute coronary syndromes.Methods: A subset of 174 patients derived from the 3,171 patients of the ESSENCE study was evaluated. Eighty-seven patients were assigned to intravenous unfractionated heparin (target aPTT: 55–85 sec) (group UH), and 87 assigned to subcutaneous enoxaparin (1 mg/kg/q12hr) (group ENOX) for a minimum of 48 hours of treatment (average duration of treatment 88±45 hours). The thrombin time, and plasma levels of anti-factor Xa activity, prothrombin fragment F 1+2, thrombin-antithrombin complex (TAT), and D-dimer, were assayed at baseline, and at or close to peak activity 24–36 hrs, and at 72–90 hrs for those remaining on treatment with antithrombotic therapy. Major ischemic and hemorrhagic events were assessed throughout hospitalization. The levels of the thrombotic markers measured at or close to peak activity at 36 hours are presented below, and compared to clinical outcome at 30 days.